In both trials, the most common side effect was gastrointestinal symptoms, which affected about half of the patients on either dose and about a quarter of patients on the placebo
However, small observational studies and clinical reports suggest some patients experience enhanced appetite suppression when both medications are used concurrently
See the CMS-0057-F prior authorization final rule for how the January 1, 2026 regulation affects UHCs mandate
A new class of weight loss medications has arrived in Australia, and it is generating significant interest from both the medical community and the general public
Taken together, these results position retatrutide as a breakthrough in comprehensive metabolic care, moving far beyond the limitations of current weight-loss and diabetes medications
Tirzepatide works on two hormones at once GLP-1 and GIP